FDA 'The Real Cost' youth tobacco evaluation survey removes gender questions to comply with EO 14168

91 FR 27062. 30-day PRA notice. FDA says it is revising the collection to remove questions relating to gender to align with EO 14168, and in answering a commenter who asked for gender items says it cannot assess gender or gender identity in the study; it keeps one sexual orientation item and one sex item. Related step (2025-07-14, 2025-13047): 90 FR 31229 (July 14, 2025), 60-day PRA notice for the extension of 'The Real Cost Campaign Outcomes Evaluation Study: Cohort' (youth longitudinal survey).